Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)
Barclays analyst Etzer Darout maintains a Buy rating for Relay Therapeutics with a $17 price target. Darout, who covers the Healthcare sector, has a 25% average return and a 56.94% success rate. Relay Therapeutics also received a Buy rating from H.C. Wainwright’s Robert Burns, while TR | OpenAI reiterated a Hold rating on November 22.
Barclays analyst Etzer Darout maintained a Buy rating on Relay Therapeutics today and set a price target of $17.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Darout covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and CytomX Therapeutics. According to TipRanks, Darout has an average return of 25.0% and a 56.94% success rate on recommended stocks.
In addition to Barclays, Relay Therapeutics also received a Buy from H.C. Wainwright’s Robert Burns in a report issued on November 10. However, on November 22, TR | OpenAI – 4o reiterated a Hold rating on Relay Therapeutics (NASDAQ: RLAY).
